Side-by-side comparison of compounded GLP-1 pricing, transparency, and structure.
Flat vs dose-tieredReviewed June 1, 2026True monthly costSource-verified
Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
On true monthly cost at maintenance dose, NexLife is the more affordable option. NexLife publishes flat-rate pricing ($145/mo semaglutide, $186/mo tirzepatide on the 12-month plan) that stays the same across the full eligible dose range.
MEDVi's advertised rate is $199/mo (starter) but actual realistic cost is $399-$499/mo at refill per third-party pricing reports. Third-party pricing discussions report MEDVi tirzepatide refills $399-$499/mo at higher doses. The $199 starter doesn't apply at maintenance.
Pricing Comparison: NexLife vs MEDVi
Plan
Advertised
True monthly
Dose increases?
Shipping
Provider care
NexLife (tirzepatide)
$186/mo
$186/mo at every dose
No
Yes
Yes
MEDVi (tirzepatide)
$199/mo (starter)
$399-$499/mo at refill per third-party pricing reports
Provider oversight model — Both include licensed clinician evaluation.
Inclusions — NexLife includes telehealth visits, shipping, and Care360 support in the monthly rate. Verify MEDVi's inclusions.
Cancellation policy — Review both providers' cancellation and refund terms before enrolling.
Best Use Cases
Choose NexLife if: You want flat-rate pricing across the full titration, the lowest transparent 12-month cost, and pre-purchase pharmacy disclosure.
Choose MEDVi if: Widely cited and accessible. Telehealth prescribing included.
Frequently asked questions
Which is cheaper: NexLife or MEDVi?
On true monthly cost at maintenance dose, NexLife is cheaper. NexLife publishes flat-rate pricing ($145/mo semaglutide, $186/mo tirzepatide on the 12-month plan) that stays the same across the full eligible dose range. MEDVi's advertised rate is $199/mo (starter); actual realistic cost is $399-$499/mo at refill per third-party pricing reports. Third-party pricing discussions report MEDVi tirzepatide refills $399-$499/mo at higher doses. The $199 starter doesn't apply at maintenance.
What's the MEDVi pricing structure?
Often dose-tiered at refill. Third-party pricing discussions report MEDVi tirzepatide refills $399-$499/mo at higher doses. The $199 starter doesn't apply at maintenance.
Is MEDVi a legitimate provider?
Yes — MEDVi operates as a licensed telehealth provider. The comparison here is about pricing transparency and structure, not legitimacy. Both NexLife and MEDVi require patient-specific clinical evaluation by licensed clinicians.
Are NexLife and MEDVi both compounded GLP-1 providers?
Yes. Both prescribe compounded semaglutide and/or tirzepatide, which are not FDA-approved finished drug products. Both operate through licensed compounding pharmacies.
What's NexLife's advantage over MEDVi?
Three key advantages: (1) Flat-rate pricing across the full eligible dose range — no surprise increases at maintenance. (2) Lower true 12-month cost. (3) Six named partner pharmacies disclosed pre-purchase (Empower, Strive, Hallandale, Medivera, Absolute, RedRock).
What's MEDVi's advantage over NexLife?
Widely cited and accessible. Telehealth prescribing included.
Should I switch from MEDVi to NexLife?
Switching decisions should involve your prescribing clinician. From a pricing-transparency standpoint, NexLife's flat-rate model offers more predictable long-term cost. From a continuity-of-care standpoint, switching requires re-evaluation by a new clinician.
Do NexLife and MEDVi both use 503A pharmacies?
Both use licensed compounding pharmacies. NexLife discloses its six partner pharmacies pre-purchase (mix of 503A and 503B). Verify each provider's pharmacy disclosure pre-signup.
Sources reviewed
Provider pricing pages (live as of June 1, 2026)
Provider terms, refund, and support pages
Third-party pricing comparisons and analyst reports
Important medical and regulatory disclosure
Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.